Indolo-pyrido-isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation of p53-miR34a axis

Molecular Oncology

Volumn 10, Issue 7, 2016, Pages 1118-1132

  Avtanski, Dimiter B ^a   Nagalingam, Arumugam ^a   Tomaszewski, Joseph E ^b   Risbood, Prabhakar ^b   Difillippantonio, Michael J ^b   Saxena, Neeraj K ^d   Malhotra, Sanjay V ^e   Sharma, Dipali ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e STANFORD CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; EMT; Indolo pyrido isoquinolin based alkaloid; Invasion; miR34a; p53

Indexed keywords

11 METHOXY 2,3,4,13 TETRAHYDRO 1H INDOLO [2',3':3,4]PYRIDO[1,2 B]ISOQUINOLIN 6 YLIUM BROMIDE; ALKALOID DERIVATIVE; ANTINEOPLASTIC AGENT; CYTOKERATIN 18; MICRORNA 34A; OCCLUDIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN P53; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UVOMORULIN; ALKALOID; ISOQUINOLINE DERIVATIVE; MICRORNA; MIRN143 MICRORNA, HUMAN; PYRIDINE DERIVATIVE; RAUWOLFIA ALKALOID; SEMPERVIRINE; TUMOR MARKER;

3' UNTRANSLATED REGION; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST EPITHELIUM CELL; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION ASSAY; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG SYNTHESIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INDUCED PLURIPOTENT STEM CELL; LABORATORY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THERAPEUTIC INDEX; TUMOR SPHEROID; UPREGULATION; XTT ASSAY; BREAST TUMOR; CANCER STEM CELL; CELL CLONE; CELL MOTION; CELL NUCLEUS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; EPITHELIUM CELL; FEMALE; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR INVASION;

ALKALOIDS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; CELL PROLIFERATION; CLONE CELLS; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; ISOQUINOLINES; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; PYRIDINES; SECOLOGANIN TRYPTAMINE ALKALOIDS; SPHEROIDS, CELLULAR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84973560668     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2016.04.003     Document Type: Article

References (52)

1. Bates, R.C., Mercurio, A.M., Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol. Biol. Cell 14 (2003), 1790–1800.
2. Beljanski, M., Beljanski, M.S., Selective inhibition of in vitro synthesis of cancer DNA by alkaloids of beta-carboline class. Exp. Cell Biol. 50 (1982), 79–87.
3. Beljanski, M., Beljanski, M.S., Three alkaloids as selective destroyers of cancer cells in mice. Synergy with classic anticancer drugs. Oncology 43 (1986), 198–203.
4. Bommer, G.T., Gerin, I., Feng, Y., Kaczorowski, A.J., Kuick, R., Love, R.E., Zhai, Y., Giordano, T.J., Qin, Z.S., Moore, B.B., MacDougald, O.A., Cho, K.R., Fearon, E.R., p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 17 (2007), 1298–1307.
5. Brooks, C.L., Gu, W., Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15 (2003), 164–171.
6. Bykov, V.J., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K.G., Selivanova, G., Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8 (2002), 282–288.
7. Chang, C.J., Chao, C.H., Xia, W., Yang, J.Y., Xiong, Y., Li, C.W., Yu, W.H., Rehman, S.K., Hsu, J.L., Lee, H.H., Liu, M., Chen, C.T., Yu, D., Hung, M.C., p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol. 13 (2011), 317–323.
8. Chang, T.C., Wentzel, E.A., Kent, O.A., Ramachandran, K., Mullendore, M., Lee, K.H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C.J., Arking, D.E., Beer, M.A., Maitra, A., Mendell, J.T., Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26 (2007), 745–752.
9. Chen, J., Marechal, V., Levine, A.J., Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13 (1993), 4107–4114.
10. Christophorou, M.A., Martin-Zanca, D., Soucek, L., Lawlor, E.R., Brown-Swigart, L., Verschuren, E.W., Evan, G.I., Temporal dissection of p53 function in vitro and in vivo. Nat. Genet. 37 (2005), 718–726.
11. Christophorou, M.A., Ringshausen, I., Finch, A.J., Swigart, L.B., Evan, G.I., The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443 (2006), 214–217.
12. Dave, B., Mittal, V., Tan, N.M., Chang, J.C., Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res., 14, 2012, 202.
13. Ding, Q., Zhang, Z., Liu, J.J., Jiang, N., Zhang, J., Ross, T.M., Chu, X.J., Bartkovitz, D., Podlaski, F., Janson, C., Tovar, C., Filipovic, Z.M., Higgins, B., Glenn, K., Packman, K., Vassilev, L.T., Graves, B., Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J. Med. Chem. 56 (2013), 5979–5983.
14. Duffy, M.J., Synnott, N.C., McGowan, P.M., Crown, J., O'Connor, D., Gallagher, W.M., p53 as a target for the treatment of cancer. Cancer Treat. Rev. 40 (2014), 1153–1160.
15. Feki, A., Irminger-Finger, I., Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol. 52 (2004), 103–116.
16. Foster, B.A., Coffey, H.A., Morin, M.J., Rastinejad, F., Pharmacological rescue of mutant p53 conformation and function. Science 286 (1999), 2507–2510.
17. Freedman, D.A., Wu, L., Levine, A.J., Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. 55 (1999), 96–107.
18. Hainaut, P., Hollstein, M., p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77 (2000), 81–137.
19. Haupt, Y., Maya, R., Kazaz, A., Oren, M., Mdm2 promotes the rapid degradation of p53. Nature 387 (1997), 296–299.
20. He, L., He, X., Lim, L.P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., Jackson, A.L., Linsley, P.S., Chen, C., Lowe, S.W., Cleary, M.A., Hannon, G.J., A microRNA component of the p53 tumour suppressor network. Nature 447 (2007), 1130–1134.
21. Jiang, D., Brady, C.A., Johnson, T.M., Lee, E.Y., Park, E.J., Scott, M.P., Attardi, L.D., Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proc. Natl. Acad. Sci. U.S.A 108 (2011), 17123–17128.
22. Kogan-Sakin, I., Tabach, Y., Buganim, Y., Molchadsky, A., Solomon, H., Madar, S., Kamer, I., Stambolsky, P., Shelly, A., Goldfinger, N., Valsesia-Wittmann, S., Puisieux, A., Zundelevich, A., Gal-Yam, E.N., Avivi, C., Barshack, I., Brait, M., Sidransky, D., Domany, E., Rotter, V., Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ. 18 (2011), 271–281.
23. Lee, J.H., Zhang, Q., Jo, S., Chai, S.C., Oh, M., Im, W., Lu, H., Lim, H.S., Novel pyrrolopyrimidine-based alpha-helix mimetics: cell-permeable inhibitors of protein-protein interactions. J. Am. Chem. Soc. 133 (2011), 676–679.
24. Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F., Zhang, C.C., Shipitsin, M., Campbell, L.L., Polyak, K., Brisken, C., Yang, J., Weinberg, R.A., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008), 704–715.
25. Martins, C.P., Brown-Swigart, L., Evan, G.I., Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127 (2006), 1323–1334.
26. Morel, A.P., Lievre, M., Thomas, C., Hinkal, G., Ansieau, S., Puisieux, A., Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One, 3, 2008, e2888.
27. Newman, D.J., Cragg, G.M., Snader, K.M., Natural products as sources of new drugs over the period 1981–2002. J. Nat. Prod. 66 (2003), 1022–1037.
28. Nicoloso, M.S., Spizzo, R., Shimizu, M., Rossi, S., Calin, G.A., MicroRNAs–the micro steering wheel of tumour metastases. Nat. Rev. Cancer 9 (2009), 293–302.
29. Rao, T.S.C., Saha, S., Raolji, G.B., Patro, B., Risbood, P., Difilippantonio, M.J., Tomaszewski, J.E., Malhotra, S.V., Microwave assisted Westphal condensation and its application to synthesis of sempervirine and related compounds. Tetrahedron Lett. 54 (2013), 487–490.
30. Ray-Coquard, I., Blay, J.Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., Geho, D., Middleton, S.A., Vassilev, L.T., Nichols, G.L., Bui, B.N., Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 13 (2012), 1133–1140.
31. Santisteban, M., Reiman, J.M., Asiedu, M.K., Behrens, M.D., Nassar, A., Kalli, K.R., Haluska, P., Ingle, J.N., Hartmann, L.C., Manjili, M.H., Radisky, D.C., Ferrone, S., Knutson, K.L., Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 69 (2009), 2887–2895.
32. Sasiela, C.A., Stewart, D.H., Kitagaki, J., Safiran, Y.J., Yang, Y., Weissman, A.M., Oberoi, P., Davydov, I.V., Goncharova, E., Beutler, J.A., McMahon, J.B., O'Keefe, B.R., Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen. J. Biomol. Screen. 13 (2008), 229–237.
33. Schon, O., Friedler, A., Bycroft, M., Freund, S.M., Fersht, A.R., Molecular mechanism of the interaction between MDM2 and p53. J. Mol. Biol. 323 (2002), 491–501.
34. Sehrawat, A., Singh, S.V., Benzyl isothiocyanate inhibits epithelial-mesenchymal transition in cultured and xenografted human breast cancer cells. Cancer Prev. Res. (Phila) 4 (2011), 1107–1117.
35. Selivanova, G., Wild type p53 reactivation: from lab bench to clinic. FEBS Lett. 588 (2014), 2628–2638.
36. Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R.S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., Bernard, D., Zhang, J., Lu, Y., Gu, Q., Shah, R.B., Pienta, K.J., Ling, X., Kang, S., Guo, M., Sun, Y., Yang, D., Wang, S., Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. U.S.A 105 (2008), 3933–3938.
37. Shaw, F.L., Harrison, H., Spence, K., Ablett, M.P., Simoes, B.M., Farnie, G., Clarke, R.B., A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J. Mammary Gland Biol. Neoplasia 17 (2012), 111–117.
38. Spike, B.T., Wahl, G.M., p53, stem cells, and reprogramming: tumor suppression beyond guarding the genome. Genes Cancer 2 (2011), 404–419.
39. Tam, W.L., Weinberg, R.A., The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat. Med. 19 (2013), 1438–1449.
40. Tavazoie, S.F., Alarcon, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P.D., Gerald, W.L., Massague, J., Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451 (2008), 147–152.
41. Thiery, J.P., Acloque, H., Huang, R.Y., Nieto, M.A., Epithelial-mesenchymal transitions in development and disease. Cell 139 (2009), 871–890.
42. Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., Liu, E.A., In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004), 844–848.
43. Ventura, A., Kirsch, D.G., McLaughlin, M.E., Tuveson, D.A., Grimm, J., Lintault, L., Newman, J., Reczek, E.E., Weissleder, R., Jacks, T., Restoration of p53 function leads to tumour regression in vivo. Nature 445 (2007), 661–665.
44. Vogelstein, B., Lane, D., Levine, A.J., Surfing the p53 network. Nature 408 (2000), 307–310.
45. Vousden, K.H., Prives, C., Blinded by the light: the growing complexity of p53. Cell 137 (2009), 413–431.
46. Welch, C., Chen, Y., Stallings, R.L., MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26 (2007), 5017–5022.
47. Willis, B.C., Liebler, J.M., Luby-Phelps, K., Nicholson, A.G., Crandall, E.D., du Bois, R.M., Borok, Z., Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. 166 (2005), 1321–1332.
48. Woods, D.B., Vousden, K.H., Regulation of p53 function. Exp. Cell Res. 264 (2001), 56–66.
49. Wu, X., Bayle, J.H., Olson, D., Levine, A.J., The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7 (1993), 1126–1132.
50. Xue, W., Zender, L., Miething, C., Dickins, R.A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., Lowe, S.W., Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007), 656–660.
51. Yang, S., Li, Y., Gao, J., Zhang, T., Li, S., Luo, A., Chen, H., Ding, F., Wang, X., Liu, Z., MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene 32 (2013), 4294–4303.
52. Zhang, Z., Chu, X.J., Liu, J.J., Ding, Q., Zhang, J., Bartkovitz, D., Jiang, N., Karnachi, P., So, S.S., Tovar, C., Filipovic, Z.M., Higgins, B., Glenn, K., Packman, K., Vassilev, L., Graves, B., Discovery of potent and orally active p53–MDM2 inhibitors RO5353 and RO2468 for potential clinical development. ACS Med. Chem. Lett. 5 (2014), 124–127.